Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study

Annals of Internal Medicine

Volumn 127, Issue 5, 1997, Pages 356-364

  Alarcón, Graciela S ^d   Kremer, Joel M ^d   Macaluso, Maurizio ^d   Weinblatt, Michael E ^d   Cannon, Grant W ^d   Palmer, William R ^d   St Clair, E William ^a   Sundy, John S ^a   Alexander, Ronald W ^d   Smith, G J Walker ^b   Axiotis, Constantine A ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Pathology   (United States)

^c KINGS COUNTY HOSPITAL CENTER   (United States)

^d Kings County Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIRHEUMATIC AGENT; GOLD; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPOALBUMINEMIA; LUNG DISEASE; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 17044442903     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-5-199709010-00003     Document Type: Article

References (73)

1. Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table: review of 587 patients treated in community practice. J Rheumatol. 1993;20:639-44.
2. Collins D, Bellamy N, Campbell J. A Canadian survey of current methotrexate prescribing practices in rheumatoid arthritis. J Rheumatol. 1994;21: 1220-3.
3. Willkens RF. Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis. Semin Arthritis Rheum. 1990;20:76-80.
4. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992;35:138-45.
5. Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol. 1987;14: 74-9.
6. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989;32:671-6.
7. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol. 1990;17: 1628-35.
8. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994;47:25-50.
9. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993;20:1850-6.
10. Sandoval DM, Alarcón GS. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol. 1995;34:49-56.
11. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33: 9-18.
12. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795-803.
13. Morgan SL, Alarcón GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol. 1993;20:929-30.
14. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158-61.
15. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121:833-41.
16. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906-8.
17. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36:329-35.
18. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-28.
19. Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie AH, Cook NJ, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994; 21:51-4.
20. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995;22:1043-7.
21. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986;29:822-31.
22. Barrera P, Van Ede A, Laan RF, Van Riel PL, Boerbooms AM, Van De Putte LB. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months [Letter]. Ann Rheum Dis. 1994;53:479-80.
23. Trenkwalder P, Eisenlohr H, Prechtel K, Lydtin H. Three cases of malignant neoplasm, pneumonitis, and pancytopenia during treatment with low-dose methotrexate. Clin Invest. 1992;70:951-5.
24. St. Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med. 1985;145: 2035-8.
25. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164-71.
26. Alarcón GS, Gispen JG, Koopman WJ. Severe reversible interstitial pneumonitis induced by low dose methotrexate [Letter]. J Rheumatol. 1989;16: 1007-8.
27. Cannon GW, Ward JR, Clegg DO, Samuelson CO Jr, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum. 1983;26:1269-74.
28. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186-95.
29. Clarysse AM, Cathey WJ, Cartwright GE, Wintrobe MM. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA. 1969; 209:1861-4.
30. Engelbrecht JA, Calhoon SL, Scherrer JJ. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum. 1983;26:1275-8.
31. Cornelissen JJ, Bakker LJ, Van der Veen MJ, Rozenberg-Arska M, Bijlsma JW. Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis. Ann Rheum Dis. 1991; 50:642-4.
32. Leduc D, De Vuyst P, Lheureux P, Gevenois P, Jacobovitz D, Yernault JC. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest. 1993;104:1620-3.
33. Weinblatt ME, Maier AL. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol Suppl. 1990;22:33-8.
34. Wyss E, Kuhn M, Luzi HP, Reinhart WH. Fatal verlaufende pneumocystis-carinii-pneumonie unter low-dose-methotrexat-und prednison-therapie wegen chronischer polyarthritis. [Fatal outcome of Pneumocystis carinii pneumonia under low-dose methotrexate and prednisone therapy for chronic rheumatoid arthritis. Case report and literature review.] Schweiz Rundsch Med Prax. 1994;83:449-52.
35. Stenger AA, Houtman PM, Bruyn GA, Eggink HF, Pasma HR. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol. 1994;23:51-3.
36. Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:242-54.
37. Scherak O, Popp W, Kolarz G, Wottawa A, Ritschka L, Braun O. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol. 1993;20:944-9.
38. Hilliquin P, Menkes CJ. Pneumopathies et traitement par le methotrexate dans la polyarthrite rheumatoide. [Lung diseases and treatment with methotrexate in rheumatoid arthritis]. Rev Pneumol Clin. 1991;47:179-82.
39. Clerc D, Brousse C, Mariette X, Bennet P, Bisson M. Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone [Letter]. Ann Rheum Dis. 1991;48:247-9.
40. Law KF, Aranda CP, Smith RL, Berkowitz KA, Ittman MM, Lewis ML. Pulmonary cryptococcosis mimicking methotrexate pneumonitis. J Rheumatol. 1993;20:872-3.
41. Perruquet JL, Harrington TM, Davis DE. Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis [Letter]. Arthritis Rheum 1983;26:1291-2.
42. O'Reilly S, Hartley P, Jeffers M, Casey E, Clancy L. Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole. Tuber Lung Dis. 1994; 75:153-5.
43. Wollner AA, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991;46:205-7.
44. Aglas F, Rainer F, Hermann J, Gretler J, Huttl E, Domej W, et al. Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthritis Rheum. 1995;38:291-2.
45. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1905;333:137-41.
46. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: J Wiley; 1989.
47. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81:1630-5.
48. Rothman KJ. Modern Epidemiology. Boston: Little, Brown; 1986:38-9.
49. Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis. 1992;51: 272-4.
50. Sostman HD, Matthay RA, Putman CE, Smith GJ. Methotrexate-induced pneumonitis. Medicine (Baltimore). 1976;55:371-88.
51. van Schaardenburg D, Hazes JM, de Boer A, Zwinderman AH, Meijers KA, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol. 1993;20:45-52.
52. Terkeltaub R, Décary F, Esdaile J. An immunogenetic study of older age onset rheumatoid arthritis. J Rheumatol. 1984;11:147-9.
53. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1984;27:522-9.
54. Lyngberg KK, Harreby M, Bentzen H, Frost B, Danneskiold-Samsoe B. Elderly rheumatoid arthritis patients on steroid treatment tolerate physical training without an increase in disease activity. Arch Phys Med Rehabil. 1994; 75:1189-95.
55. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991;28:6-10.
56. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol Suppl. 1990;20:12-9.
57. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously -predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986;13:841-5.
58. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916-20.
59. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579-81.
60. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol. 1982;9:224-8.
61. Leigh JP, Fries JF. Correlations between education and arthritis in the 1971-1975 NHANES I. Soc Sci Med. 1994;38:575-83.
62. Alarcón GS, Koopman WJ, Acton RT, Barger BO. HLA-Bw35 and gold toxicity in rheumatoid arthritis [Letter]. Arthritis Rheum. 1985;28:236-7.
63. Alarcón GS, Barger BO, Acton RT, Koopman WJ. HLA antigens and gold toxicity in American blacks with rheumatoid arthritis. Rheumatol Int. 1986;6: 13-7.
64. Barger BO, Acton RT, Koopman WJ, Alarcón GS. DR antigens and gold toxicity in white rheumatoid arthritis patients. Arthritis Rheum. 1984;27: 601-5.
65. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med. 1995;98:156-68.
66. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med. 1993;119:1067-71.
67. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 1984;27:267-76.
68. Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980;303:300-2.
69. Situnayake RD, Grindulis KA, McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987;46:177-83.
70. Louie S, Lillington GA. Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax. 1988;41:703-4.
71. Elsasser S, Dalquen P, Soler M, Perruchoud AP. Methotrexate-induced pneumonitis: appearance four weeks after discontinuation of treatment. Am Rev Resp Dis. 1989;140:1089-92.
72. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull. 1978;25:208-11.
73. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 1995;38: 1115-9.